TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04866316

Intervention type: OTHER
Intervention: There is no active intervention as this is a service evaluation
Description: There is no active intervention as this is a service evaluation

Intervention type: OTHER
Intervention: There is no active intervention as this is a service evaluation
Description: There is no active intervention as this is a service evaluation
Study: NCT03796624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micropure 1.2.3.
Description: Implantation of intraocular lens (IOL). Name: MicroPure 1.2.3. It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per patient will be implanted

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PODEYE
Description: Implantation of intraocular lens (IOL). Name: PODEYE It is a monofocal intraocular lens consisting of hydrophobic acrylic material. The IOL will be implanted in the contralateral eye of the same patient already implanted with Micropure 1.2.3.
Study: NCT05129826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the association between periodontitis and malnutrition status
Description: be determine the association between periodontitis and malnutrition status in older adult.
Study: NCT01227681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF(granulocyte-colony stimulating factor) is planned injected subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF(granulocyte-colony stimulating factor) is planned injected subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride (NaCl) 0.9 %
Study: NCT04052100

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The standard preoperative measures will consist of a recommendation for physical activity and advice on tobacco smoking cessation and reduction of alcohol intake. In addition, patients who suffer from iron deficient anemia will receive intravenous iron and those at risk of malnutrition (Malnutrition Universal Screening Tool ≥2 (www.bapen.org.uk/pdfs/must/must_full.pdf)) or that require weight control for obesity (IMC≥30) will perform a nutrition intervention by a nutritionist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation
Description: The experimental group will also carry out a prehabilitation program consisting in:~A. A motivational interview to reinforce the patient's motivation and generate a commitment in relation to the objectives of the program.~B. A physical activity promotion program to increase the number of daily steps of patients, measured by a wristband and a mobile App.~C. A supervised high-intensity exercise training program. D. An individualized nutritional optimization plan with dietary advice and protein supplementation (if necessary). Educational material and motivational messages will be sent through a mobile App.~F. Psychological support through weekly Mindfulness sessions (1.5 hours duration). Educational material and motivational messages will be sent through a mobile App.~E. A smoking cessation program consisting psycho-cognitive therapy combined with pharmacological treatment. Educational material and motivational messages will be sent through a mobile App.
Study: NCT01396642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Emollient
Description: Neonates in this group will receive topical emollient application with coconut oil twice a day till 28th day of life
Study: NCT00401856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: 50mg oral route

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is identical to eplerenone but the active ingredient is absent
Study: NCT01952574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered by study site staff once a month (QM) as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered by study site staff once a month (QM) as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered by study site staff once a month (QM) as a subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erenumab
Description: Administered by study site staff once a month (QM) as a subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by study site staff once a month (QM) as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab PFS
Description: Erenumab supplied in a single-use prefilled syringe for self-administration in the CHU substudy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab AI/Pen
Description: Erenumab supplied in a single-use autoinjector/pen for self-administration in the CHU substudy
Study: NCT02082613

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lord´s procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sclerotherapy
Study: NCT01583387

Intervention type: OTHER
Group type: OTHER
Intervention: 1-Increased water intake regimen
Description: Arm 1-Intervention

Intervention type: OTHER
Group type: OTHER
Intervention: 2-Non-modified water intake regimen
Description: Arm 2-Control
Study: NCT03892642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Induction phase:~* once weekly for weeks 1-6,~* once every 2 weeks at week 8, 10, and 12~Maintenance phase:~* Once every week for weeks 1-3~* Once every 2 weeks starting at week 5, until the next BCG treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: Induction phase (cycle 1):~• Once weekly for weeks 1-6~Maintenance phase (Month 3, 6, and 12):~• Once weekly for 3 weeks
Study: NCT00832455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: Montelukast 4-5 mg for 12 weeks, oral tablet
Study: NCT04389164

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue-engineered skin grafts of autologous scar dermal scaffolds
Description: 1. scar excision. The thickness of scar tissue in the middle of scar is removed with a roller cutter and the thickness is about 0.01 -- 0.02mm.~2. take autologous skin slices of the patient with an electric skin knife, cut out a small piece of skin, and prepare autologous epidermal basal cell suspension for use;The rest of the skin should be the same size as the wound.~3. the prepared autogenous scar dermal stent was grafted onto the scar resection wound surface, and the prepared autoepidermal basal cells were sprayed between the mesh and on the dermal stent, and autologous skin slices were grafted onto the wound surface and fixed with pressure bandaging;~4. after the operation, the outer dressing should be changed regularly according to the conventional treatment, and the wound surface condition should be observed and recorded according to the experimental scheme.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue-engineered skin grafts of autologous scar dermal scaffolds
Description: 1. scar excision. The thickness of scar tissue in the middle of scar is removed with a roller cutter and the thickness is about 0.01 -- 0.02mm.~2. take autologous skin slices of the patient with an electric skin knife, cut out a small piece of skin, and prepare autologous epidermal basal cell suspension for use;The rest of the skin should be the same size as the wound.~3. the prepared autogenous scar dermal stent was grafted onto the scar resection wound surface, and the prepared autoepidermal basal cells were sprayed between the mesh and on the dermal stent, and autologous skin slices were grafted onto the wound surface and fixed with pressure bandaging;~4. after the operation, the outer dressing should be changed regularly according to the conventional treatment, and the wound surface condition should be observed and recorded according to the experimental scheme.
Study: NCT04369144

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dynamic Scapular Recognition exercise
Description: The intervention group received continual vertical downward correction using a standardized rigid tape. A hypoallergenic tape (Hypafix; BSN Medical GmbH, Hamburg, Germany) was used with 50% to 75% tension. Two rigid tapes were applied; the first one is placed from just superior to the midpoint of the superior border of the scapula to the level of T12 and the second tapes were placed from just superior to the superior angle of the scapula to the level of T12. The level of T12 was used as the end of both taps to increase the lever arm of the applied force and to decrease the incidence of peeling off of the tape. No tape was applied from the lateral angle of the scapula because it might impair the upward rotation of the scapula. Both taps were performed after each session and removed immediately before the next session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Scapular Recognition exercise
Description: The intervention group received continual vertical downward correction using a standardized rigid tape. A hypoallergenic tape (Hypafix; BSN Medical GmbH, Hamburg, Germany) was used with 50% to 75% tension. Two rigid tapes were applied; the first one is placed from just superior to the midpoint of the superior border of the scapula to the level of T12 and the second tapes were placed from just superior to the superior angle of the scapula to the level of T12. The level of T12 was used as the end of both taps to increase the lever arm of the applied force and to decrease the incidence of peeling off of the tape. No tape was applied from the lateral angle of the scapula because it might impair the upward rotation of the scapula. Both taps were performed after each session and removed immediately before the next session
Study: NCT03192488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine
Description: Cetirizine tablet 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Gelatin placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Gelatin placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: Exposure to a 14.3% oxygen environment simulating an altitude of 3,000m/9,000ft

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypoxia
Description: Exposure to a 14.3% oxygen environment simulating an altitude of 3,000m/9,000ft
Study: NCT03328507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI4900
Description: BLI4900 Bowel Preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG Control
Description: Polyethylene glycol-based bowel preparation
Study: NCT03239249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IKO-model
Description: A systematic model for drop-out prevention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Schools randomized to control group (22) work as previously with school dropout
Study: NCT00937976

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Periodontal Scaling and Root Planing
Description: Participants will take antibiotics prior to dental treatment. Periodontal treatment or a deep cleaning (with local anesthesia or numbing) will be performed to remove plaque and tartar around the teeth and gums. A small amount of antibiotics (minocycline) will be placed around the gums to help fight bacteria and inflammation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Periodontal Scaling and Root Planing
Description: Participants will take antibiotics prior to dental treatment. Periodontal treatment or a deep cleaning (with local anesthesia or numbing) will be performed to remove plaque and tartar around the teeth and gums. A small amount of antibiotics (minocycline) will be placed around the gums to help fight bacteria and inflammation.
Study: NCT02178657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell intra-arterial injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell intra-arterial injection
Study: NCT01788631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson
Description: Regadenoson is an A2AR agonist that is a coronary vasodilator. It is chemically described as adenosine, 2-\[4-\[(methylamino)carbonyl\]-1H-pyrazol-1-yl\]-, monohydrate. Its molecular formula is C15H18N8O5. Regadenoson has an FDA indication for use in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. It has lower affinity for non-A2A adenosine receptor subtypes thought to be associated with some of the adverse effects associated with non-selective adenosine receptor agonists, which increase extracellular adenosine by blocking its uptake into cells. The maximal plasma concentration of regadenoson is achieved within 1 to 4 minutes after injection and parallels the onset of the pharmacodynamic response. Its half-life is approximately 2 to 4 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This study uses 0.9% Normal Saline (NS) as placebo. This is a sterile sodium chloride solution usually used to replenish fluids and electrolytes. It contains no additives, and is a standard solution used as placebo in clinical trials where the study drug is administration intravenously. NS will be prepared by investigational pharmacy.
Study: NCT01842360

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will receive daily dose of placebo during 12 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV130
Description: The subjects will receive daily dose of MV130 during 12 months
Study: NCT04129489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Synthetic Cannabidiol, dissolved in pharmaceutical grade olive oil at a concentration of 5% will be administered orally
Study: NCT03520777

Intervention type: OTHER
Group type: OTHER
Intervention: Art Intervention
Description: Type of artist intervention will be determined by the subject and the assigned artist.
Study: NCT02182843

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellentra VCBM
Description: Cellentra™ VCBM is an allogenic bone graft containing naturally occurring viable donor cells intended for homologous use in the repair, replacement, reconstruction or supplementation of the recipient's tissue in musculoskeletal defects.
Study: NCT00938769

Intervention type: OTHER
Group type: OTHER
Intervention: Self-Efficacy Training for Caregivers
Description: The Enhanced Caregiver Training intervention will be delivered to informal caregivers of cancer patients before hospital discharge who are randomly selected to receive this intervention. Subjects in the treatment group will receive an individualized experiential caregiver training in strategies for managing patient's symptoms and in the use of pleasant imagery and muscle relaxation to manage stress.~2-hour in-person instruction of home care issues for caregivers of patients with cancer.

Intervention type: OTHER
Group type: OTHER
Intervention: Comparison Conditions for Caregivers
Description: Subjects randomly selected to participate in the attention control training will receive an informational session about cancer and resources for caregiving.~2-hour counseling session for cancer caregivers to locate community support resources
Study: NCT04328038

Intervention type: OTHER
Intervention: Survey
Description: Patient fill out a survey containing: Demographic Information, medical history, several Questionnaires about Health Literacy, Well Being/HRQoL and Fatigue

Intervention type: OTHER
Intervention: Survey
Description: Patient fill out a survey containing: Demographic Information, medical history, several Questionnaires about Health Literacy, Well Being/HRQoL and Fatigue
Study: NCT00288626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF) and prednisone
Description: Growth factor regimen; occurs at study entry

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine, etoposide, cytarabine, and melphalan (BEAM)
Description: High-dose chemotherapy; occurs seven or more days following collection of autologous graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplant
Description: Occurs after growth factor regimen and collection of autologous graft
Study: NCT01446536

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Checklist cohort
Description: CHF discharge checklist was used arbitrarily by their treating physicians in addition to the standard therapy
Study: NCT03525223

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Change of dialysate [Na+]
Description: Stepwise modulation of dialysate sodium concentration by 1-2 mmo/l per week

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Change of dialysate [Na+]
Description: Stepwise modulation of dialysate sodium concentration by 1-2 mmo/l per week
Study: NCT02021344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Health First Aid
Description: Originally developed in 2001, MHFA is a 12-hour course comprised of six modules, covering depression, anxiety, psychosis, substance abuse, eating disorders, and self-harm. Each module includes information about the mental health-related problems (e.g., signs and symptoms), advice on how to respond appropriately, and interactive activities to enhance the learning process. Some modules include videos with perspectives of individuals recovering from mental disorders and examples of how to effectively use the MHFA intervention. Program participants learn how to help individuals in crisis and also how to recognize early warning signs and intervene before mental health problems progress to crises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Health First Aid
Description: Originally developed in 2001, MHFA is a 12-hour course comprised of six modules, covering depression, anxiety, psychosis, substance abuse, eating disorders, and self-harm. Each module includes information about the mental health-related problems (e.g., signs and symptoms), advice on how to respond appropriately, and interactive activities to enhance the learning process. Some modules include videos with perspectives of individuals recovering from mental disorders and examples of how to effectively use the MHFA intervention. Program participants learn how to help individuals in crisis and also how to recognize early warning signs and intervene before mental health problems progress to crises.
Study: NCT00991237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency
Description: Pulsed Radiofrequency
Study: NCT02063477

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo composition is for 1 gelule: 250 mg maltodextrin + 30 mg magnesium stearate; total weight: 280 mg/gelule

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oligopin®
Description: Oligopin® PUR' expert (%) is a red brown powder extracted from the bark of the Maritime Pine (Pinus pinaster) with composition:~- TOTAL POLYPHENOL CONTENT \> 96~1. MONOMERS + PHENOLIC ACIDS 30~2. DIMERS \>15~3. OTHER OLIGOMERS 50~PROCYANIDINS CONTENT (GPC) \> 67~The Oligopin composition is for 1 gelule: 75 mg Oligopin + 175 mg maltodextrine + 30 mg magnesium stearate: total weight: 280 mg/gelule
Study: NCT03107039

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A 12 week resistance exercise curriculum

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: A 12 week health education curriculum
Study: NCT02721277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOFlipid
Description: SMOFlipid contains a mixture of 4 different lipid sources: soybean oil which provides essential fatty acids, olive oil which is high in monounsaturated fatty acids that are less susceptible to lipid peroxidation than polyunsaturated fatty acids, medium-chain triglycerides which show a faster metabolic clearance than long-chain triglycerides, and fish oil which provides the supply of omega-3 fatty acids.
Study: NCT02613832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EPAP
Description: The EPAP will be applied with a Spring Load Valve Resistor (Vital Signs, Totowa, NJ, USA), adjusted with a pressure of 10 cmH2O. The Spring Load Valve Resistor will be connected to the expiratory branch of the T-tube. Duration of intervention: 5 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath Stacking
Description: The BS will be performed by a T-tube with a one-way inspiratory valve and the expiratory branch occluded. The expiratory occlusion is maintain until observed the presence of a plateau in the impedance plethysmogram by EIT, which corresponds to the absence of inspired air displacement or when a maximum time of 40 seconds was attained. Durantion of intervention:Three BS interventions will be performed at one minute intervals between them.
Study: NCT03070600

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Universal PrEP Counseling
Description: Counseling at universal sites, will use a standardized counseling script to state that PrEP is available for women at risk for HIV, explain that HIV prevalence in the region is high, and will note that women with HIV positive partners or who don't know their partner's status may be at risk. Counseling will specify that women may have their own reasons to feel at risk or to want PrEP. Following standardized counseling, women will select PrEP at the same visit or will be allowed to deliberate on the decision and come back at the next visit with a decision. Women will be informed that it is advisable to use PrEP if they know their partner is HIV positive or if they do not know their partner's status and will be encouraged to bring untested partners to clinic if status is unknown.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted PrEP Counseling
Description: Following enrollment, the targeted PrEP clinics will provide two inter-related innovations over two ANC visits. In the targeted PrEP clinics, any of the following three criteria can trigger enhanced PrEP counseling. A participant that meets any one of these criteria will receive PrEP counseling during the study visit where the criteria is met:~1. Risk Score \>6 (Risk score includes male partner status known/unknown, syphilis infection, and lifetime number of male partners) or any National AIDS and STI Control Programme (NASCOP) risk factors~2. participant declines partner self-tests regardless of partner HIV status, and/or~3. their partner declines self-testing or tests positive.
Study: NCT00003909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: motexafin gadolinium
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlatives studies